David E Diamond

US Patent:

7511118, Mar 31, 2009

Filed:

Jun 16, 2006

Appl. No.:

11/454633

Inventors:

Liping Liu - Manassas VA, US
Adrian Bot - Valencia CA, US
Jian Gong - Northridge CA, US
David Diamond - West Hills CA, US

Assignee:

MannKind Corporation - Valencia CA

International Classification:

A61K 38/04
A61K 38/00
A61K 51/00

US Classification:

530327, 530326, 514 2, 426 169

Abstract:

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

US Patent:

7511119, Mar 31, 2009

Filed:

Jun 16, 2006

Appl. No.:

11/455278

Inventors:

Liping Liu - Manassas VA, US
Adrian Bot - Valencia CA, US
David C. Diamond - West Hills CA, US

Assignee:

MannKind Corporation - Valencia CA

International Classification:

A61K 38/04
A61K 38/00
A61K 51/00

US Classification:

530327, 530326, 514 2, 426 169

Abstract:

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

US Patent:

7605227, Oct 20, 2009

Filed:

Jun 16, 2006

Appl. No.:

11/454300

Inventors:

Liping Liu - Manassas VA, US
Adrian Bot - Valencia CA, US
David C. Diamond - West Hills CA, US

Assignee:

MannKind Corporation - Valencia CA

International Classification:

A61K 38/04
A61K 38/00
A61K 51/00

US Classification:

530327, 530326, 514 2, 426 169

Abstract:

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally, classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

US Patent:

8202841, Jun 19, 2012

Filed:

Jun 17, 2005

Appl. No.:

11/156253

Inventors:

Liping Liu - Manassas VA, US
Zhidong Xie - Manassas VA, US
David C. Diamond - West Hills CA, US

Assignee:

MannKind Corporation - Valencia CA

International Classification:

C07K 7/06
C07K 7/08

US Classification:

514 215, 514 213, 514 214, 514 216, 530324, 530325, 530326, 530327, 530328, 436 86

Abstract:

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

US Patent:

8354380, Jan 15, 2013

Filed:

Jun 17, 2005

Appl. No.:

11/155929

Inventors:

Liping Liu - Manassas VA, US
Adrian Bot - Valencia CA, US
David C. Diamond - West Hills CA, US

Assignee:

MannKind Corporation - Valencia CA

International Classification:

C07K 14/74
C07K 7/06
C07K 7/08

US Classification:

514 216, 514 215, 514 212, 530328, 530326, 530324

Abstract:

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

US Patent:

20050130920, Jun 16, 2005

Filed:

Jul 20, 2004

Appl. No.:

10/895523

Inventors:

John Simard - Vancouver, CA
Xiang-Dong Lei - Germantown MD, US
David Diamond - West Hills CA, US

International Classification:

A61K048/00
C12N015/85

US Classification:

514044000, 435455000

Abstract:

Disclosed herein are vaccines and methods for inducing an immune response against cancer cells and cells infected with intracellular parasites. Vaccines having housekeeping epitopes are disclosed. The housekeeping epitope is formed by housekeeping proteasomes in peripheral cells, but not by professional antigen presenting cells. A vaccine containing a housekeeping epitope that is derived from an antigen associated with a peripheral target cell can thus direct an immune response against the target cell. Methods of treatment are also disclosed, which involve administering a vaccine having a housekeeping epitope.

US Patent:

20060057673, Mar 16, 2006

Filed:

Jun 17, 2005

Appl. No.:

11/156369

Inventors:

Liping Liu - Manassas VA, US
Adrian Bot - Valencia CA, US
David Diamond - West Hills CA, US

International Classification:

C07K 14/74
C07H 21/04
C12P 21/06

US Classification:

435069100, 530302000, 530350000, 435320100, 435325000, 536023500

Abstract:

Some embodiments relate to analogs of peptides corresponding to class I MHC-restricted T cell epitopes and methods for their generation. These analogs can contain amino acid substitutions at residues that directly interact with MHC molecules, and can confer improved, modified or useful immunologic properties. Additionally classes of analogs, in which the various substitutions comprise the non-standard residues norleucine and/or norvaline, are disclosed.

US Patent:

20060099269, May 11, 2006

Filed:

Aug 23, 2005

Appl. No.:

11/210709

Inventors:

Wayman Cheatham - Columbia MD, US
Marshall Grant - Newtown CT, US
Per Fog - Bedford Hills NY, US
David Diamond - West Hills CA, US

Assignee:

MannKind Corporation - Valencia CA

International Classification:

A61K 31/519
A61K 9/14

US Classification:

424489000, 514252160, 514262100

Abstract:

Provided herein are compositions of 1) diketopiperazine salts of PDE5 inhibitors, and 2) DKP microparticles having a PDE5 inhibitors thereon, as well as methods for the pulmonary delivery of these compositions for the treatment of pulmonary hypertension and sexual dysfunction(s).

Author:

David J. Diamond

ISBN #:

0312313896

Author:

David Diamond

ISBN #:

0142300535

Author:

David Diamond

ISBN #:

0066620724

Author:

David Diamond

ISBN #:

0066620732

Author:

David Diamond

ISBN #:

0634001957

Author:

David Diamond

ISBN #:

0634017055

Author:

David Diamond

ISBN #:

0452286484

Author:

David Diamond

ISBN #:

0821219057